Occurrence of irAEs after Immune Checkpoint Inhibitor Rechallenge: An Updated Meta-Analysis

Figure 4

(a) Subgroup analyses of the association between ICI rechallenge and all-grade irAE occurrence after ICI rechallenge. CI, confidence interval; ICIs, immune checkpoint inhibitors; irAEs, immune-related adverse events; NSCLC, non-small-cell lung cancer; OR, odds ratio. (b) Subgroup analyses of the association between ICI rechallenge and high-grade irAE occurrence after ICI rechallenge. CI, confidence interval; ICIs, immune checkpoint inhibitors; irAEs, immune-related adverse events; NSCLC, non-small-cell lung cancer; OR, odds ratio. High-grade was considered grade ≥3.

(a)

(b)